CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the [...]
BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part [...]
DATE: January 3, 2019 CIRCULOGENE Expands Molecular Diagnostics Testing Footprint To Asia-Pacific Region Strategic partnership broadens cancer-targeted molecular diagnostics and immunotherapy testing to rapidly growing Asia-Pacific market. BIRMINGHAM, Ala.– CIRCULOGENE, advancing precision medicine through molecular genetics [...]
FOR IMMEDIATE RELEASE DATE: December 20, 2018 CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019 Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK [...]
CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]
CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]
REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by CIRCULOGENE, this pilot [...]
CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]
Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016 BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology [...]
AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer BIRMINGHAM, Ala., – [...]